CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Dual-faced circRNAs: orchestrating immunosuppression and activation in the lung cancer microenvironment.
Dual-faced circRNAs: orchestrating immunosuppression and activation in the lung cancer microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
环状RNA(circRNA)是一类以共价闭合环状结构为特征的非编码RNA,由于其高稳定性、组织特异性表达及多维调控能力,已成为肺癌肿瘤免疫微环境(TIME)中的关键调控因子。本文系统综述了最新研究进展,阐明了circRNA通过多种分子机制调控TIME中免疫细胞功能状态的过程,包括作为竞争性内源RNA(ceRNA)吸附微小RNA(miRNA)、与RNA结合蛋白(RBP)相互作用,以及在某些情况下编码功能性多肽。circRNA具有双向调控能力:一方面,它们可通过调节免疫检查点分子的表达、影响效应免疫细胞(如CD8 + T细胞)的浸润和活性、招募免疫抑制细胞(如调节性T细胞和M2型巨噬细胞)以及调控免疫信号通路来促进肿瘤免疫逃逸;另一方面,它们也可以激活抗肿瘤免疫应答。
此外,本文还探讨了circRNA作为液体活检生物标志物在肺癌诊断和预后中的潜力,以及其在疫苗、circRNA增强型CAR-T 疗法和编码免疫调节因子的制剂等治疗策略中的转化前景。尽管面临机制复杂、递送效率低和安全性问题等挑战,多组学技术、新型递送系统和基因编辑工具的发展为开发靶向circRNA的精准疗法提供了方向,这些疗法旨在重塑肺癌免疫微环境并克服免疫治疗耐药。
Circular RNAs (circRNAs), a class of non-coding RNAs characterized by covalently closed-loop structures, have emerged as key regulators in the tumor immune microenvironment (TIME) of lung cancer, owing to their high stability, tissue-specific expression, and multidimensional regulatory capabilities. This review systematically synthesizes the latest research progress and elucidates the processes by which circRNAs regulate the functional states of immune cells in the TIME through diverse molecular mechanisms, including acting as competing endogenous RNAs (ceRNAs) to sequester microRNAs (miRNAs), interacting with RNA-binding proteins (RBPs), and in some cases, encoding functional polypeptides.
CircRNAs possess bidirectional regulatory capacities: they can promote tumor immune evasion by modulating the expression of immune checkpoint molecules, influencing the infiltration and activity of effector immune cells (e. g. , CD8 + T cells), recruiting immunosuppressive cells (e. g. , regulatory T cells and M2-type macrophages), and regulating immune signaling pathways; meanwhile, they can also activate antitumor immune responses.
Furthermore, the review explores the potential of circRNAs as liquid biopsy biomarkers for lung cancer diagnosis and prognosis, as well as their translational prospects in therapeutic strategies including vaccines, circRNA-enhanced CAR-T therapy, and formulations encoding immunomodulatory factors.
Despite challenges such as complex mechanisms, low delivery efficiency, and safety concerns, the development of multi-omics technologies, novel delivery systems, and gene-editing tools provides directions for the development of precision therapies targeting circRNAs, which aim to reshape the lung cancer immune microenvironment and overcome immunotherapy resistance.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。